NuvOx welcomes all inquiries regarding potential opportunities for collaboration or investment. Please e-mail your inquiries to John McGonigle, Business Development, at jmcgonigle@nuvoxpharma.com  

pipeline partnership at NuvOx Pharma


  1. In stroke, animal studies show that DDFPe can reduce neurological damage by 85%. A randomized, placebo controlled Phase Ib/II trial tested acute ischemic stroke patients given placebo or low, medium, or high doses of NVX-208. The primary endpoint was safety, which was demonstrated at all three dose levels. A secondary endpoint was the modified Rankin Scale (mRS), a measure of how independently patients can live in the weeks and months after the stroke. The high dose group suggested improvement in the mRS at 30 days and 90 days.
  2. In oncology, DDFPe is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation, chemotherapy, and/or immunotherapy. It has completed enrollment in a Phase Ib/II clinical trial in glioblastoma multiforme patients receiving radiation therapy and chemotherapy. The trial showed statistically significant evidence of tumor re-oxygenation (p=0.015) with no significant change in the oxygenation of the normally oxygenated brain tissue (p=0.65). Early results show evidence of increased overall survival. The FDA has allowed an Investigational New Drug application for a Phase II clinical trial.
  3. In sickle cell crisis, a pre-clinical study of acute chest syndrome in mice saw 0% survival in controls and 100% survival in treated animals.
  4. In traumatic brain injury (TBI), animal studies by the US Navy showed an increase in brain tissue oxygen tension with DDFPe administration following TBI in rats, and a reduction in ischemic neurons and spongiosis after TBI in pigs.
  5. In myocardial infarction, studies in mice show that DDFPe can reduce the damage to cardiac tissue from myocardial infarction by 72% when DDFPe is given after myocardial infarction is induced.
  6. In hemorrhagic shock, several studies by the US Army showed 0% survival in controls and 100% survival in treated animals. NuvOx has partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd., to develop the product in China – NuvOx retains rights in the rest of the world for treatment of hemorrhagic shock.

8 Replies to “Pipeline”

  1. We are a call center with 22 years in the market at chula vista california, we are interested in work with laboratories for work in campaigns , our experiences are Health Care , Cancer , DME.
    Waiting for you comments

  2. Hello,
    I am with OUTFRONT Media and we provide outdoor advertising opportunities on static and digital billboards throughout the valley. We also provide advertising on the light rail and we have a mobile network that reaches consumers on their cell phones through banner ads. It is a great way to tell your brand story and grow your business. Please contact me at your convenience to discuss this further.
    Thank you,

  3. Just curious, does DDFPe reduce damage by reactive nitrogen species like peroxynitrite? Seems like nitrotyrosine in serum proteins was once used as a marker for peroxynitrate production.
    Did you guys ever get into those 1D and 2D Blue native gels of mitochondrial electron transport chain complexes? A while back (2014) glutathionylation of a complex I thiol was thought to be the start of a vicious cycle. Just curious as to where your stuff stands with some of the redox theory that was popular 5 years ago.
    Good luck and continued success. Nice stuff you have going.

  4. Have you ever thought about creating an ebook or guest authoring on other sites?
    I have a blog based upon on the same information you discuss
    and would love to have you share some stories/information.
    I know my readers would value your work. If you are even remotely interested,
    feel free to send me an e mail.

Leave a Reply

Your email address will not be published.